Health Care's Sweet 16 Stocks: Celgene vs. Biogen
Spring is in the air, and the annual NCAA March Madness college basketball tournament has once again captivated the nation. Of course, that also means Cinderella stories like Florida Gulf Coast have busted the brackets of would-be basketball prognosticators.
Here at The Motley Fool, we decided to stick with what we know, trading our basketball picks in for stock picks. We formed our own Sweet 16 filled with the top Big Pharma and Big Biotech stocks in a winner-take-all tournament determined by the collective intelligence of our CAPS community.
This matchup is a heavyweight bout between Celgene and Biogen Idec. Watch and find out which stock gets eliminated and which will advance to the next round.
Can Celgene continue to soar?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand-new premium report on Celgene. To claim your copy today simply click here now.
The article Health Care's Sweet 16 Stocks: Celgene vs. Biogen originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Follow him on Twitter: @MotleyDavid.Max Macaluso, Ph.D. and The Motley Fool also have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.